Head-to-head evidence
Carisbamate vs Rufinamide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Carisbamate
Developed by SK Biopharmaceuticals Co., Ltd.
NCT00425282 · Phase 3 · completed
The study was randomized and double-blind with 566 participants, and its primary endpoint was the clinical measure of change in seizure frequency. However, no results are posted and the registry record does not clearly identify a comparator arm, so the primary endpoint cannot be judged as met or missed.
Next expected readout: February 2027 · NCT05219617 (registry estimate)
Rufinamide
Marketed by Eisai and partners
NCT00334958 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 356 participants, and its primary clinical endpoint was change in partial-seizure frequency. The reported median change favored rufinamide (-23.25% versus -9.80% with placebo), but the registry does not state whether this primary comparison was statistically significant, so the result remains unclear.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carisbamate's landscape · Rufinamide's landscape